Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Paper Based Urine Test Detects Cancer

By LabMedica International staff writers
Posted on 13 May 2014
A technology that combines synthetic biomarkers with a paper-based urine test can detect colorectal cancer and thrombosis in just a few minutes.

The new technique uses exogenous agents injected into the patient, which bind with tumor proteins. More...
A paper strip test then easily detects the synthetic biomarkers in the patient’s urine and the molecular detection system brings a number of existing technologies together in a novel way.

Scientists at the Massachusetts Institute of Technology (MIT; Cambridge, MA, USA) developed nanoparticles that target diseased tissue, such as a tumor, at which point reporter compounds that had been bound to the nanoparticles are released and cleared into the urine. They designed two synthetic biomarkers, one associated with colorectal cancer and another that was specific to blood clots, a common sign of cardiovascular problems. The team demonstrated their ability to detect these compounds in urine from murine models of these diseases using a paper strip coated with targeted antibodies, a strategy called paper lateral flow assay (LFA).

The investigators focused on one group of signals called matrix metalloproteinases (MMPs), because MMPs function to help cancer cells to metastasize. They printed capture antibodies into four parallel test lines relative to a control line and analyzed urine samples that contained one of the four reporters. Similar to the enzyme-linked immunosorbent assay (ELISA) results obtained previously, only the test lines printed with the cognate capture antibody developed a positive signal, highlighting the LFA’s specificity and the capacity to detect distinct reporters with single spatially encoded paper strips.

Sangeeta Bhatia, MD, PhD, a professor and senior author of the study said, “When we invented this new class of synthetic biomarker, we used a highly specialized instrument to do the analysis. For the developing world, we thought it would be exciting to adapt it instead to a paper test that could be performed on unprocessed samples in a rural setting, without the need for any specialized equipment. The simple readout could even be transmitted to a remote caregiver by a picture on a mobile phone.” The study was published on February 24, 2014, in the Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Related Links:

Massachusetts Institute of Technology



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The assay serves as an adjunctive tool in evaluating patients suspected of B-cell lymphoproliferative disorders (photo courtesy of Shutterstock)

First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies

Accurate identification of clonal immunoglobulin heavy chain (IGH) gene rearrangements is central to evaluating suspected B-cell lymphoproliferative disorders, where a single B-cell clone yields a defining... Read more

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.